IL-4 receptor a polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist

The outcome for this genetic analysis was the ratio of LAR after 4 weeks of treatment with either placebo or pitrakinra compared with baseline levels. [...]an increased LAR ratio corresponds to a reduction in late-phase FEV1 response to antigen after treatment or an improvement in lung function relative to baseline measurements. Because the cynomolgus genomic IL4RA DNA sequence was not available, we directly sequenced 100 bp surrounding IL4RA exons, the proximal promoter, and 3' untranslated regions by using DNA from 23 monkeys.